Data on WaferGen's SmartChip(TM) System to be Presented at 3rd Annual Rediscovering...

Data on WaferGen's SmartChip(TM) System to be Presented at 3rd Annual
Rediscovering Biomarkers Conference

FREMONT, Calif., July 7 /PRNewswire-FirstCall/ -- WaferGen Biosystems, Inc.
(OTC Bulletin Board: WGBS), a leading developer of state-of-the-art genetic
analysis systems, today announced that data on the company's SmartChip
Real-Time PCR System will be presented at GTCbio's 3rd Annual Rediscovering
Biomarkers Conference. The data will be presented by Kumar Kastury, Ph.D.,
WaferGen's vice president, research and technical operations, as part of an
oral presentation on Friday, July 10. The conference is being held July 9-10
in San Diego, California.

Details of the oral presentation are as follows:

Title: SmartChip(TM): A High-Throughput Nano-Volume Real-Time PCR
System

Session: New Discovery Technologies

Time: 8:30 a.m. PDT on Friday, July 10

Location: Sunset Room, The Dana Hotel on Mission Bay

Summary: A discussion offering an overview of the novel, high-throughput
SmartChip Real-Time PCR System, as well as the SmartChip's
analytical performance to date. Furthermore, Dr. Kastury will
present differential gene expression data between matched normal
lung and tumor tissue samples that has been gathered using the
SmartChip platform.

WaferGen's SmartChip system is currently the focus of ongoing gene expression
research collaborations with scientific teams at the University of Pittsburgh
School of Medicine and the University of Texas, Southwestern. These programs
are designed to leverage the SmartChip's innovative capabilities to identify
and validate therapeutically-relevant gene expression biomarkers in areas
including chronic obstructive pulmonary disease (COPD), idiopathic pulmonary
fibrosis (IPF), lung cancer and wound healing. WaferGen believes this
research may lead to the discovery of specific genes responsible for causing
these diseases and conditions. In turn, this critical genetic information may
ultimately provide physicians with new tools for determining accurate disease
prognosis in patients, while also potentially providing drug developers with
information necessary for the creation of targeted therapeutics. The
SmartChip platform is also the focus of a genotyping research collaboration
with scientists in the Institute for Genome Sciences and Policy at Duke
University Medical Center. The focus of this program is the validation of
single-nucleotide polymorphisms (SNPs) that are related to breast cancer, as
well as an examination of the impact the validated SNPs have on patients'
disease prognosis and response to treatment.

About the SmartChip Real-Time PCR System

The SmartChip Real-Time PCR System(TM) is designed as the first whole genome,
high-throughput gene expression real-time polymerase chain reaction (PCR)
platform. WaferGen believes the SmartChip Real-Time PCR System will be the
first platform to combine the high-throughput capability and cost efficiencies
of existing microarrays, with the sensitivity and accuracy of real-time PCR.
This innovative system, combined with next-generation chemistry and optimized
assays being developed by WaferGen, promises to provide industry-leading
throughput levels, while offering discovery and validation capabilities in a
single step. The result is expected to be the ability to conduct gene
expression and genotyping research at a fraction of the time and cost
currently produced by existing instrument systems. It is estimated that the
genetic analysis market alone (comprised of gene expression and genotyping
analysis) had approximately $2.4 billion in worldwide revenues in 2006 ($1.74
billion for gene expression and $650 million for genotyping).

About WaferGen

WaferGen Biosystems, Inc. is a leader in the development, manufacture and sale
of state-of-the-art systems for genetic analysis for the life science and
pharmaceutical industries. The company is actively developing its
SmartChip(TM) product for the gene expression and genotyping markets.
SmartChip is being developed as the first whole genome, high throughput gene
expression real-time PCR platform. This innovative system, combined with
next-generation chemistry and optimized assays being developed by WaferGen,
promises to deliver significant speed and cost advantages to researchers in
the gene expression and genotyping markets. Based on collaborations
established with leading research institutions, WaferGen believes that the
SmartChip Real-Time PCR System is positioned as the platform of choice for
biomarker discovery and validation. WaferGen currently markets its
SmartSlide(TM) family of products to companies and organizations involved in
stem cell and cell biology research. SmartSlide represents the first fluidics
integrated micro-incubators enabling cell biology and stem cell research.

Forward-Looking Statements

This press release contains certain "forward-looking statements". Such
statements include statements relating to the recent strengthening of the
leadership team of the company and other statements relating to future events
or to the company's future financial performance and are not historical facts,
including statements which may be preceded by the words "intends," "may,"
"will," "plans," "expects," "anticipates," "projects," "predicts,"
"estimates," "aims," "believes," "hopes," "potential" or similar words.

Forward-looking statements are not guarantees of future performance, are based
on certain assumptions and are subject to various known and unknown risks and
uncertainties, many of which are beyond the control of the company. Actual
results may differ materially from the expectations contained in the
forward-looking statements. Factors that may cause such differences include
the risks that: (i) the company may be unsuccessful in commercially developing
its products or in achieving market acceptance of new and relatively unproven
technologies; (ii) the company will need to raise additional capital to meet
its business requirements in the future and the company may not be able to do
so on reasonable terms or at all; (iii) the company's proprietary intellectual
property rights may not adequately protect its products and technologies; and
(iv) the company expects intense competition in its target markets, including
from companies that have much greater resources than the company, and there
can be no assurance that the company will be able to compete effectively.
More detailed information about the company and the risk factors that may
affect the realization of forward-looking statements is set forth in the
company's filings with the Securities and Exchange Commission, including the
company's Annual Report on Form 10-K for the year ended December 31, 2008 and
the company's Quarterly Report on Form 10-Q for the quarter ended March 31,
2009. Investors and security holders are urged to read this document free of
charge on the SEC's web site at www.sec.gov. The company does not undertake to
publicly update or revise its forward-looking statements as a result of new
information, future events or otherwise.

Contact:

Vida Communication (Media)
On Behalf of WaferGen
Tim Brons
415-675-7400
tbrons@vidacommunication.com

SOURCE WaferGen Biosystems, Inc.

Tim Brons of Vida Communication, +1-415-675-7400,
tbrons@vidacommunication.com, for WaferGen